[go: up one dir, main page]

MA50817B1 - Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide - Google Patents

Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Info

Publication number
MA50817B1
MA50817B1 MA50817A MA50817A MA50817B1 MA 50817 B1 MA50817 B1 MA 50817B1 MA 50817 A MA50817 A MA 50817A MA 50817 A MA50817 A MA 50817A MA 50817 B1 MA50817 B1 MA 50817B1
Authority
MA
Morocco
Prior art keywords
ynoyl
pyrazin
imidazo
pyrrolidin
pyridin
Prior art date
Application number
MA50817A
Other languages
English (en)
Other versions
MA50817A (fr
Inventor
Jerry Evarts
Tjeerd Barf
Fritz Blatter
Tim Ingallinera
Edwin Aret
Cecile Krejsa
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50817(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MA50817A publication Critical patent/MA50817A/fr
Publication of MA50817B1 publication Critical patent/MA50817B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)

Abstract

La présente demande concerne des formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl )-n-(pyridin-2-yl)benzamide base libre et aux formes cristallines de ses sels, compositions de celles-ci et utilisations en médecine.
MA50817A 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide MA50817B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28

Publications (2)

Publication Number Publication Date
MA50817A MA50817A (fr) 2021-04-21
MA50817B1 true MA50817B1 (fr) 2021-10-29

Family

ID=56363881

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50817A MA50817B1 (fr) 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Country Status (29)

Country Link
US (7) US9796721B2 (fr)
EP (4) EP3954690B1 (fr)
JP (3) JP6829215B2 (fr)
KR (2) KR102688052B1 (fr)
CN (2) CN113480542B (fr)
AU (3) AU2016286548B2 (fr)
CA (1) CA2991096A1 (fr)
CL (1) CL2017003445A1 (fr)
CY (3) CY1124519T1 (fr)
DK (3) DK3317281T3 (fr)
ES (3) ES2797987T3 (fr)
FI (2) FI3954690T3 (fr)
HR (3) HRP20230417T1 (fr)
HU (3) HUE056008T2 (fr)
IL (3) IL274066B (fr)
LT (3) LT3613745T (fr)
MA (1) MA50817B1 (fr)
MD (1) MD3317281T2 (fr)
MX (2) MX378495B (fr)
MY (1) MY193514A (fr)
PL (3) PL3613745T3 (fr)
PT (3) PT3613745T (fr)
RS (3) RS60411B1 (fr)
RU (1) RU2018103913A (fr)
SG (1) SG10201913796UA (fr)
SI (3) SI3613745T1 (fr)
SM (3) SMT202000304T1 (fr)
WO (1) WO2017002095A1 (fr)
ZA (2) ZA201800329B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211813T1 (hr) * 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
RS60411B1 (sr) 2015-07-02 2020-07-31 Acerta Pharma Bv Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida
JP7083760B2 (ja) 2016-06-29 2022-06-13 テサロ， インコーポレイテッド 卵巣癌の治療方法
US10899767B2 (en) * 2016-10-05 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
WO2018115965A1 (fr) * 2016-12-23 2018-06-28 Acerta Pharma Bv Formes solides de composés d'imidazopyrazine
WO2018148961A1 (fr) * 2017-02-20 2018-08-23 杭州领业医药科技有限公司 Forme cristalline du sel acp-196, procédé de préparation, composition pharmaceutique et utilisation associés
SG11201908977SA (en) * 2017-03-27 2019-10-30 Tesaro Inc Niraparib formulations
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
US10717740B2 (en) 2017-06-13 2020-07-21 Dr. Reddy's Laboratories Limited. Solid forms of acalabrutinib and process for preparation thereof
CA3073293A1 (fr) * 2017-08-29 2019-03-07 Apotex Inc. Nouvelles formes cristallines d'acalabrutinib
KR20200058496A (ko) 2017-09-26 2020-05-27 테사로, 인코포레이티드 니라파립 제제
WO2019105359A1 (fr) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Forme cristalline de l'acalabrutinib, son procédé de préparation et son application
KR20200106511A (ko) 2018-01-05 2020-09-14 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 아칼라브루티닙의 신규 결정형 및 그 제조방법 및 용도
WO2019159097A1 (fr) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Nouvelles formes polymorphes cristallines d'acalabrutinib
WO2019205812A1 (fr) * 2018-04-26 2019-10-31 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
EP3587421A1 (fr) 2018-06-29 2020-01-01 Sandoz AG Formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
IL322382A (en) 2018-08-29 2025-09-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridine-2-yl)-benzamide
WO2020053795A2 (fr) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Procédé de préparation d'acalabrutinib et de ses intermédiaires
WO2020065667A1 (fr) 2018-09-25 2020-04-02 Cipla Limited Nouveaux polymorphes d'acalabrutinib, un inhibiteur de la tyrosine kinase de bruton
EP3947386A1 (fr) 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Formes à l'état solide d'acalabrutinib
WO2020225831A1 (fr) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (fr) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
WO2021239893A1 (fr) 2020-05-29 2021-12-02 Bend Research, Inc. Dispersion solide amorphe d'acalabrutinib
PE20230992A1 (es) 2020-06-19 2023-06-23 Acerta Pharma Bv Formas farmaceuticas de maleato de acalabrutinib
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
US20240315978A1 (en) * 2021-01-13 2024-09-26 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (fr) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions et méthodes pour traiter des lymphomes avec un inhibiteur de cdk7 en combinaison avec un inhibiteur de btk
WO2023205279A1 (fr) * 2022-04-19 2023-10-26 The Johns Hopkins University Spectroscopie raman améliorée avec addition de composés aromatiques
EP4662214A1 (fr) * 2023-02-09 2025-12-17 Apotex Inc. Formes cristallines de maléate d'acalabrutinib
WO2025125383A1 (fr) 2023-12-11 2025-06-19 Synthon B.V. Formes cristallines d'hydrogénomaléate d'acalabrutinib

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
BRPI0415395A (pt) 2003-10-15 2006-12-12 Osi Pharm Inc composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
EP2305682A1 (fr) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. Inhibiteurs hétérobicycliques de la protéine kinase à anneau bicyclique substitué en 6,6
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
KR101655455B1 (ko) 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 일일 1회 투여를 위한 트라조돈 조성물
RS51843B (sr) 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. KONDENZOVANI BICIKLIČNI m TOR INHIBITORI
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US7651687B2 (en) 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
PL2529621T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
EP2139487B1 (fr) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
EP2231147A2 (fr) 2007-12-13 2010-09-29 Novartis AG Combinaisons d'agents thérapeutiques pour le traitement du cancer
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
KR101661383B1 (ko) 2010-02-08 2016-09-29 머크 샤프 앤 도메 비.브이. 8-메틸-1-페닐-이미다졸［1,5-ａ］피라진 화합물
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011152351A1 (fr) 2010-05-31 2011-12-08 小野薬品工業株式会社 Dérivé de purinone
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
CA2840413A1 (fr) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Procedes et compositions visant a inhiber la resorption osseuse
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
CA2841887A1 (fr) 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
ES2950569T3 (es) * 2011-07-19 2023-10-11 Merck Sharp & Dohme (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk
KR20230109775A (ko) 2011-10-19 2023-07-20 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3333166B1 (fr) * 2012-05-23 2019-11-06 Nerviano Medical Sciences S.R.L. Procédé pour la préparation de n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-méthyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
TW201441234A (zh) 2013-01-23 2014-11-01 Merck Sharp & Dohme Ｂｔｋ抑制劑
HK1224173A1 (zh) 2013-03-14 2017-08-18 Pharmacyclics Llc 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
WO2014143807A2 (fr) 2013-03-15 2014-09-18 Stromatt Scott Anticorps anti-cd37 et polythérapie par antagoniste de la voie bcr pour le traitement de malignités b et de troubles des lymphocytes b
EP2983670A4 (fr) 2013-04-08 2017-03-08 Pharmacyclics LLC Combinaison thérapeutique à base d'ibrutinib
JP6368353B2 (ja) 2013-04-08 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用
WO2015018522A1 (fr) 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
WO2015057992A1 (fr) * 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
JP2016540053A (ja) 2013-12-05 2016-12-22 アセルタ ファーマ ビー．ブイ． Ｐｉ３ｋ阻害剤とｂｔｋ阻害剤の治療的組み合わせ
RU2648236C2 (ru) 2013-12-13 2018-03-23 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
WO2015110923A2 (fr) 2014-01-21 2015-07-30 Acerta Pharma B.V. Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
RS60411B1 (sr) * 2015-07-02 2020-07-31 Acerta Pharma Bv Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida

Also Published As

Publication number Publication date
JP2018522877A (ja) 2018-08-16
HUE049989T2 (hu) 2020-11-30
MX2020014163A (es) 2022-09-29
HUE062258T2 (hu) 2023-10-28
JP2021073235A (ja) 2021-05-13
US11820777B2 (en) 2023-11-21
LT3954690T (lt) 2023-05-25
PT3613745T (pt) 2021-10-14
PT3317281T (pt) 2020-06-18
LT3317281T (lt) 2020-07-27
JP2022120156A (ja) 2022-08-17
RS60411B1 (sr) 2020-07-31
IL274066A (en) 2020-06-30
KR102688052B1 (ko) 2024-07-25
MD3317281T2 (ro) 2020-07-31
KR20180048593A (ko) 2018-05-10
DK3954690T3 (da) 2023-06-06
US20180208596A1 (en) 2018-07-26
FI3954690T3 (fi) 2023-05-31
EP3954690A1 (fr) 2022-02-16
FI4209493T3 (fi) 2026-01-19
EP3613745A1 (fr) 2020-02-26
IL293821A (en) 2022-08-01
DK3613745T3 (da) 2021-10-18
PL3954690T3 (pl) 2023-08-14
US10167291B2 (en) 2019-01-01
IL274066B (en) 2022-07-01
US9796721B2 (en) 2017-10-24
HK1250511A1 (en) 2018-12-21
HRP20211511T1 (hr) 2021-12-24
KR20240115937A (ko) 2024-07-26
SMT202000304T1 (it) 2020-07-08
AU2022291635A1 (en) 2023-02-02
HRP20200934T1 (hr) 2020-09-18
JP6829215B2 (ja) 2021-02-10
CY1126103T1 (el) 2023-11-15
EP3317281A1 (fr) 2018-05-09
EP4209493B1 (fr) 2025-11-12
ZA201800329B (en) 2022-04-28
US20240199622A1 (en) 2024-06-20
SI3954690T1 (sl) 2023-07-31
ES2895802T3 (es) 2022-02-22
RU2018103913A3 (fr) 2019-12-31
PL3317281T3 (pl) 2020-11-02
RS64195B1 (sr) 2023-06-30
MA50817A (fr) 2021-04-21
US20220348582A1 (en) 2022-11-03
SMT202300165T1 (it) 2023-07-20
HRP20230417T1 (hr) 2023-07-07
US11059829B2 (en) 2021-07-13
ES2946489T3 (es) 2023-07-19
AU2022291635B2 (en) 2024-06-27
AU2016286548B2 (en) 2020-12-10
EP3954690B1 (fr) 2023-04-05
SMT202100597T1 (it) 2021-11-12
HUE056008T2 (hu) 2022-01-28
IL256633A (en) 2018-02-28
US10640509B2 (en) 2020-05-05
EP4209493A1 (fr) 2023-07-12
DK3317281T3 (da) 2020-06-15
CY1124519T1 (el) 2022-03-24
JP7091494B2 (ja) 2022-06-27
SG10201913796UA (en) 2020-03-30
US20200255437A1 (en) 2020-08-13
CA2991096A1 (fr) 2017-01-05
US20220177476A1 (en) 2022-06-09
EP3317281B1 (fr) 2020-04-22
SI3317281T1 (sl) 2020-08-31
AU2020277123B2 (en) 2022-09-29
RU2018103913A (ru) 2019-08-02
ES2797987T3 (es) 2020-12-04
LT3613745T (lt) 2021-10-11
RS62455B1 (sr) 2021-11-30
MX2018000179A (es) 2018-06-27
WO2017002095A1 (fr) 2017-01-05
CN108349978A (zh) 2018-07-31
IL256633B (en) 2020-05-31
CN113480542B (zh) 2025-07-25
US20170029428A1 (en) 2017-02-02
CN108349978B (zh) 2021-07-23
US20190337949A1 (en) 2019-11-07
PL3613745T3 (pl) 2022-01-31
MY193514A (en) 2022-10-17
AU2020277123A1 (en) 2020-12-24
CL2017003445A1 (es) 2018-05-11
EP3613745B1 (fr) 2021-09-01
ZA202000300B (en) 2022-03-30
PT3954690T (pt) 2023-06-06
MX378495B (es) 2025-03-11
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
AU2016286548A1 (en) 2018-02-01
SI3613745T1 (sl) 2021-12-31

Similar Documents

Publication Publication Date Title
MA50817B1 (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
EA201590748A1 (ru) Противовирусные соединения против rsv
NZ710270A (en) Pyridone amides as modulators of sodium channels
CR20170263A (es) Forma cristalina de sulfato acido de (s)-n- (5- ( (r)-2- (2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201591379A1 (ru) Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
TR201309037A2 (tr) Dapoksetin ve bir pde5 inhibitörü içeren yeni efervesan saşe formülasyonları.
MA57556B1 (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MA57504B1 (fr) Forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide